EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 3.0

Real-World Effectiveness of Budesonide/Glycopyrronium/Formoterol (BGF) Fixed-Dose Combination in Patients with COPD (RECORD Study): A Prospective Observational Study

Henrik Watz, Michael Watt iD, Tamsin Morris iD, Matthias Saathoff, Annika Fernandez Milano, Dinesh Shrikrishna iD, Dave Singh, Marija Halbach

International Journal of Chronic Obstructive Pulmonary Disease · 2026-10 · Volume 21 · 1-16

DOI: 10.2147/copd.s598569 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2026-10. Verfasst von Henrik Watz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department III (Respiratory Medicine), University of Luebeck, Luebeck, Germany. Hauptthemen laut MEDLINE: Bronchodilator Agents, Budesonide, Formoterol Fumarate, Glycopyrrolate. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchodilator AgentsBudesonideFormoterol FumarateGlycopyrrolateLungMuscarinic AntagonistsPulmonary Disease, Chronic ObstructiveAgedFemaleHumansMaleMiddle AgedAdministration, InhalationAdrenergic beta-2 Receptor AgonistsDisease ProgressionDrug CombinationsGermanyGlucocorticoidsPatient Reported Outcome MeasuresPatient SatisfactionProspective StudiesRecovery of FunctionSeverity of Illness IndexTime FactorsTreatment OutcomeUnited Kingdom

Stichwörter der Autor:innen

COPD symptom controlcardiovascular comorbiditiespatient-reported outcomesreal-world evidencetreatment satisfactiontriple inhaler therapy

Substanzen

Adrenergic beta-2 Receptor AgonistsBronchodilator AgentsBudesonideDrug CombinationsFormoterol FumarateGlucocorticoidsGlycopyrrolateMuscarinic Antagonists

Autor:innen und Institutionen

  • Medical Department III (Respiratory Medicine), University of Luebeck, Luebeck, Germany.
  • Airway Research Center North (ARCN), German Center for Lung Research (DZL), Luebeck, Germany.
  • Real World Evidence, AstraZeneca, London, UK.
  • Clinical Operations, Alcedis, Giessen, Germany.
  • Real World Evidence, IQVIA, Frankfurt, Germany.
  • Department of Respiratory Medicine, Musgrove Park Hospital, Taunton, UK.

ORCID-Profile: Michael Watt, Tamsin Morris, Dinesh Shrikrishna

Zitieren

APA

Watz, H., Watt, M., Morris, T., Saathoff, M., Fernandez Milano, A., Shrikrishna, D., Singh, D., & Halbach, M. (2026). Real-World Effectiveness of Budesonide/Glycopyrronium/Formoterol (BGF) Fixed-Dose Combination in Patients with COPD (RECORD Study): A Prospective Observational Study. International Journal of Chronic Obstructive Pulmonary Disease, Volume 21, 1-16. https://doi.org/10.2147/copd.s598569

Vancouver

Watz H, Watt M, Morris T, Saathoff M, Fernandez Milano A, Shrikrishna D, et al. Real-World Effectiveness of Budesonide/Glycopyrronium/Formoterol (BGF) Fixed-Dose Combination in Patients with COPD (RECORD Study): A Prospective Observational Study. International Journal of Chronic Obstructive Pulmonary Disease. 2026;Volume 21:1-16. doi:10.2147/copd.s598569

BibTeX
@article{Watz2026,
  author = {Watz, Henrik and Watt, Michael and Morris, Tamsin and Saathoff, Matthias and Fernandez Milano, Annika and Shrikrishna, Dinesh and Singh, Dave and Halbach, Marija},
  title = {Real-World Effectiveness of Budesonide/Glycopyrronium/Formoterol (BGF) Fixed-Dose Combination in Patients with COPD (RECORD Study): A Prospective Observational Study},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2026},
  volume = {Volume 21},
  pages = {1--16},
  doi = {10.2147/copd.s598569}
}
Kostenlos starten →